Story perspectives

Lung Cancer Therapeutics Market Set to Surge to $15.86 Billion by 2032

9/2/2025

31 7

Summary

Story summary

The U.S. lung cancer therapeutics market is expected to grow from USD 9.51 billion in 2024 to USD 15.86 billion by 2032.
Advances in targeted therapies and immuno-oncology are driving this growth.
Key players include AstraZeneca, Merck, and Bristol-Myers Squibb, with targeted therapy as the market leader.
Immunotherapies accounted for over 40% of revenue in 2024, with continued growth anticipated.
North America holds the largest market share, while Asia-Pacific is the fastest-growing region.

1 of 1

Story summary

The U.S. lung cancer therapeutics market is expected to grow from USD 9.51 billion in 2024 to USD 15.86 billion by 2032.
Advances in targeted therapies and immuno-oncology are driving this growth.
Key players include AstraZeneca, Merck, and Bristol-Myers Squibb, with targeted therapy as the market leader.
Immunotherapies accounted for over 40% of revenue in 2024, with continued growth anticipated.
North America holds the largest market share, while Asia-Pacific is the fastest-growing region.